✦ LIBER ✦

LETTER TO THE EDITOR: Oral Phosphodiesterase Type 5 Inhibitors: Nonerectogenic Beneficial Uses—A Comment

✍ Scribed by Rachel K. Hames; Celia Wilson; David Goldmeier

Book ID: 114828316
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 35 KB
Volume: 6
Category: Article
ISSN: 1743-6095
DOI: 10.1111/j.1743-6109.2009.01263.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Oral Phosphodiesterase Type 5 Inhibitors

Oral Phosphodiesterase Type 5 Inhibitors: Nonerectogenic Beneficial Uses

✍ Taymour Mostafa 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB

How to optimise treatment of erectile dy

How to optimise treatment of erectile dysfunction above and beyond the beneficial effects of a phosphodiesterase type 5 inhibitor

✍ Louis Gooren 📂 Article 📅 2008 🏛 Dougmar Publishing Group, Inc. 🌐 English ⚖ 117 KB

1253 A SYSTEMATIC REVIEW AND META-ANALYS

1253 A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE USE OF PHOSPHODIESTERASE TYPE 5 INHIBITORS (PDE5-IS) FOR LOWER URINARY TRACT SYMPTOMS (LUTS) SECONDARY TO BENIGN PROSTATIC HYPERPLASIA (BPH)

✍ Gacci, Mauro; Corona, Giovanni; Salvi, Matteo; Vignozzi, Linda; McVary, Kevin T. 📂 Article 📅 2012 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 112 KB

Reply to Jin-Qiu Yuan, Zu-Yao Yang, and

Reply to Jin-Qiu Yuan, Zu-Yao Yang, and Chen Mao's Letter to the Editor re: Mauro Gacci, Giovanni Corona, Matteo Salvi, et al. A Systematic Review and Meta-Analysis on the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination with α-Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. Eur Urol 2012;61:994–1003: Meta-analysis on the Use of PDE5 Inhibitors for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia, According to the Recommendations of the Cochrane

✍ Mauro Gacci; Giovanni Corona; Matteo Monami; Sergio Serni; Vincenzo Mirone; Marc 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 142 KB